Factors predictive of acute regional toxicity after isolated limb infusion with Melphalan and Actinomycin D in Melanoma patients

Annals of Surgical Oncology

Volumn 16, Issue 5, 2009, Pages 1184-1192

  Kroon, Hidde M ^a   Moncrieff, Marc ^a,b   Kam, Peter C A ^a,b   Thompson, John F ^c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SYDNEY CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARBON DIOXIDE; CREATINE KINASE; DACTINOMYCIN; DEXAMETHASONE; HEPARIN CALCIUM; MELPHALAN; TROPISETRON;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; AMPUTATION; ARTERY THROMBOSIS; ARTICLE; BLISTER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; COMPARTMENT SYNDROME; DRUG HYPERSENSITIVITY; EDEMA; ERYTHEMA; FEMALE; HUMAN; HYPERTHERMIA; INFUSION; ISOLATED LIMB INFUSION; LIMB TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA AND VOMITING; POSTOPERATIVE NAUSEA AND VOMITING; RATING SCALE; RISK FACTOR; THROMBOSIS PREVENTION; VEIN THROMBOSIS; WIEBERDINK SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DACTINOMYCIN; EXTREMITIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; SKIN NEOPLASMS;

EID: 64249144998     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0323-x     Document Type: Article

References (44)

1. BC Vrouenraets OE Nieweg BB Kroon 1996 Thirty-five years of isolated limb perfusion for melanoma: indications and results Br J Surg. 83 1319 1328
2. DJ Grünhagen JH de Wilt AN van Geel AM Eggermont 2006 Isolated limb perfusion for melanoma patients: a review of its indications and the role of tumor necrosis factor-α Eur J Surg Oncol. 32 371 380
3. A Sanki PCA Kam JF Thompson 2007 Long-term results of hyperthermic, isolated limb perfusion for melanoma Ann Surg. 4 591 596
4. JF Thompson JHW De Wilt 2001 Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role Ann Surg Oncol. 8 564 565
5. BC Vrouenraets JM Klaase OE Nieweg BB Kroon 1998 Toxicity and morbidity of isolated limb perfusion Semin Surg Oncol. 14 224 231
6. Thompson JF, Kam PCA, de Wilt JHW, Lindnér P. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of Melanoma. London: Martin Dunitz; 2004. p. 429-37.
7. P Lindnér A Doubrovsky PCA Kam JF Thompson 2002 Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma Ann Surg Oncol. 9 127 136
8. MS Brady K Brown A Patel C Fisher W Marx 2006 A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity Ann Surg Oncol. 13 1123 1129
9. HM Kroon M Moncrieff PC Kam JF Thompson 2008 Outcomes following isolated limb infusion for melanoma. A 14-year experience Ann Surg Oncol. 15 3003 3013
10. BC Vrouenraets AMM Eggermont AAM Hart JM Klaase AN van Geel OE Nieweg 2001 Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-α versus toxicity after melphalan alone Eur J Surg Oncol. 27 390 395
11. JF Thompson S Eksborg PCA Kam C Ingvar DF Yau DT Lai 1996 Determinants of acute regional toxicity following isolated limb perfusion for melanoma Melanoma Res. 6 267 271
12. BC Vrouenraets GA Hart AM Eggermont JM Klaase BN van Geel OE Nieweg 1999 Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma J Am Coll Surg. 188 522 530
13. J Wieberdink C Benckhuysen RP Braat EA van Slooten GA Olthuis 1982 Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions Eur J Cancer Clin Oncol. 18 905 910
14. P Lindnér JF Thompson JH De Wilt M Colman PC Kam 2004 Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma Eur J Surg Oncol. 30 433 439
15. R Mian MA Henderson D Speakman D Finkelde J Ainslie A McKenzie 2001 Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion Can J Surg. 44 189 192
16. JF Thompson RC Waugh RPM Saw PCA Kam 1994 Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion Reg Cancer Treat. 7 188 192
17. JF Thompson PCA Kam RC Waugh CR Harman 1998 Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion Semin Surg Oncol. 14 238 247
18. JF Thompson PC Kam 2004 Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion J Surg Oncol 1 88 1 3
19. JF Thompson JA Hunt KF Shannon PC Kam 1997 Frequency and duration of remission after isolated limb perfusion for melanoma Arch Surg. 132 903 907
20. DT Lai C Ingvar JF Thompson 1993 The value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma Reg Cancer Treat. 1 36 39
21. JM Klaase BBR Kroon AN van Geel AMM Eggermont HR Franklin AAM Hart 1994 Patient and treatment related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities Am J Surg. 167 618 620
22. Liénard D, Lejeune F, Autier Ph, Sales F, Ghanem G. Physiological and pharmacokinetics parameters in isolation perfusion of the limbs. In: Lejeune FJ, Chaudhuri PK, Das Gupta T, editors. Malignant Melanoma: Medical and Surgical Management. New York: McGraw-Hill; 1994. p. 241-8.
23. HB Mann DR Whitney 1947 On a test of whether one of two random variables is stochastically larger than the other Ann Math Stat. 18 50 60
24. JM Klaase BBR Kroon AN van Geel J van Wijk HR Franklin AMM Eggermont 1994 Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion J Am Coll Surg. 178 564 572
25. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatments (WHO Offset Publication No. 48). Geneva: World Health Organization; 1979.
26. BC Vrouenraets BB Kroon JM Klaase OE Nieweg GW van Slooten JA van Dongen 1995 Severe acute regional toxicity after normothermic or "mild" hyperthermic isolated limb perfusion with melphalan for melanoma Melanoma Res. 5 425 431
27. BC Vrouenraets JM Klaase BB Kroon BN van Geel AM Eggermont HR Franklin 1995 Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions Arch Surg. 130 43 47
28. JM Klaase BB Kroon GW van Slooten C Benckhuijsen 1992 Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma Reg Cancer Treat. 4 309 312
29. GM Beasley RP Petersen J Yoo 2008 Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion Ann Surg Oncol. 15 2195 2205
30. Scott RN, Blackie R, Kerr DJ, et al. Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In: Jakesz R, Rainer H, editors. Progress in Regional Cancer Therapy. Berlin-Heidelberg: Springer-Verlag; 1990. p. 195-200.
31. JM Klaase BBR Kroon JH Beijnen GW van Slooten JA van Dongen 1994 Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb Br J Cancer. 70 151 153
32. MS Roberts ZY Wu GA Siebert YF Anissimov JF Thompson BM Smithers 2001 Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy Melanoma Res. 11 423 431
33. JF Thompson GA Siebert YG Anissimov BM Smithers A Doubrovsky CD Anderson 2001 Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies Br J Cancer. 85 157 165
34. MS Roberts ZY Wu GA Siebert JF Thompson BM Smithers 2001 Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat Melanoma Res. 11 611 618
35. GM Beasley MI Ross DS Tyler 2008 Future directions in regional treatment strategies for melanoma and sarcoma Int J Hyperthermia. 24 301 309
36. Wieberdink J. Physiological Considerations Regarding Isolation Perfusion of the Extremities. Meppel, The Netherlands: Krips Repro; 1978.
37. BC Vrouenraets BB Kroon SA van de Merwe JM Klaase MP Broekmeyer-Reurink GW van Slooten 1996 Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: a pilot study Eur Surg Res. 28 235 244
38. JF Thompson PD Good PC Kam 1994 Hyperthermic isolated limb perfusion in the treatment of melanoma: technical aspects Reg Cancer Treat. 1 147 154
39. ET Krementz RD Carter CM Sutherland JH Muchmore RF Ryan O Creech Jr 1994 Regional chemotherapy for melanoma. A 35-year experience Ann Surg. 220 520 535
40. EM Noorda BC Vrouenraets OE Nieweg AN van Geel AM Eggermont BBR Kroon 2002 Safety and efficacy of isolated limb perfusion in elderly melanoma patients Ann Surg Oncol. 9 968 974
41. KM McMasters 2002 Isolated limb perfusion in elderly melanoma patients Ann Surg Oncol. 9 939 940
42. BC Vrouenraets BB Kroon JM Klaase JM Bonfrer OE Nieweg GW van Slooten 1997 Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion Ann Surg Oncol. 4 88 94
43. EJ Sonneveld BC Vrouenraets BN van Geel AM Eggermont JM Klaase OE Nieweg 1996 Systemic toxicity after isolated limb perfusion with melphalan for melanoma Eur J Surg Oncol. 22 521 527
44. JF Thompson DJ Malouf S Merzliakov PC Kam 1993 Efficacy of singledose ondansetron in the prevention of post-operative nausea and vomiting following isolated limb perfusion with cytostatic agents Reg Cancer Treat. 4 177 182